Drug Search Results
More Filters [+]

Venlafaxine

Alternative Names: venlafaxine, effexor, venlafaxin, venlafaxinexr, Venlafaxina, efexor
Latest Update: 2024-06-28
Latest Update Note: Clinical Trial Update

Product Description

Venlafaxine is FDA approved to treat and manage symptoms of depression, social anxiety disorder, and cataplexy. Off-label, venlafaxine can be used for attention deficit disorder, fibromyalgia, diabetic neuropathy, complex pain syndromes, hot flashes, migraine prevention, post-traumatic stress disorder, obsessive-compulsive disorder, and premenstrual dysphoric disorder. Venlafaxine may be used independently or as part of combination therapy with other drugs.  (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK535363/)

Mechanisms of Action: SNR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Venlafaxine

Countries in Clinic: Japan

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Depressive Disorder, Major|Generalized anxiety disorder

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

jRCT2031220234

P3

Recruiting

Generalized anxiety disorder

2025-05-17

jRCT2031220156

P3

Recruiting

Generalized anxiety disorder

2025-04-30

jRCT2031220238

P3

Recruiting

Depressive Disorder, Major

1970-01-01

jRCT2031220357

P3

Recruiting

Depressive Disorder, Major

1970-01-01

Recent News Events